| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Src
EphB4 and Src kinases. AZ12672857 is a potent inhibitor of EphB4 with an IC50 of 1.3 nM. It also inhibits Src kinase activity, as demonstrated by its inhibition of Src-transfected 3T3 cell proliferation with an IC50 of 2 nM. By inhibiting these kinases, the compound modulates cell proliferation, migration, and survival signaling pathways. |
|---|---|
| ln Vitro |
Merely little CYP P450 inhibition is demonstrated by AZ12672857 (IC50=5 μM against 2C9 and 3A4, >10 μM against 1A4, 2D6, and 2C19). AZ12672857 has an IC50 of 240 nM for p-KDR inhibition in HUVEC and 58 nM for p-PDGFR-β inhibition in MG63 cell line[1].
AZ12672857 inhibits EphB4 autophosphorylation in transfected CHO-K1 cells with an IC50 of 9 nM. It inhibits cell proliferation of Src-transfected 3T3 cells with an IC50 of 2 nM. It also shows IC50s of 240 nM for p-KDR in HUVEC and 58 nM for p-PDGFR-β in MG63 cells. It moderately inhibits CYP P450 with IC50s of 5 μM for 2C9 and 3A4. |
| ln Vivo |
In vivo, AZ12672857 would be expected to exert anti-tumor effects through its inhibition of EphB4 and Src kinases. By blocking these kinases, it could inhibit tumor cell proliferation, angiogenesis, and metastasis. Its effects in vivo would be assessed in animal models of cancer and other diseases where EphB4 and Src signaling are implicated.
|
| Enzyme Assay |
In vitro enzyme activity assays are used to characterize AZ12672857 as a kinase inhibitor. Recombinant EphB4 or Src kinases are incubated with their substrates in the presence of varying concentrations of the compound, and kinase activity is measured to determine IC50 values. For EphB4, the IC50 is 1.3 nM.
|
| Cell Assay |
Cellular assays for AZ12672857 involve treating cancer cell lines or kinase-transfected cells with the compound and measuring inhibition of kinase phosphorylation and cell proliferation. For example, inhibition of EphB4 autophosphorylation in CHO-K1 cells is measured with an IC50 of 9 nM, and inhibition of Src-transfected 3T3 cell proliferation is measured with an IC50 of 2 nM.
|
| Animal Protocol |
In vivo efficacy of AZ12672857 would be evaluated in animal models of cancer. The compound could be administered orally or via injection, and its effects on tumor growth, angiogenesis, and metastasis would be assessed. Its ability to inhibit EphB4 and Src kinases makes it a potential tool for studying these targets in vivo.
|
| ADME/Pharmacokinetics |
AZ12672857 has a molecular formula of C26H30N8O2 and a molecular weight of 486.57. It is soluble in DMSO (25 mg/mL) and has a purity of ≥98%. As a small-molecule kinase inhibitor, its pharmacokinetic properties would be characteristic of this class, with potential for oral bioavailability. The compound should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for AZ12672857. As a kinase inhibitor, its safety profile would be an important consideration. Potential toxicities could be related to its effects on EphB4 and Src signaling in normal tissues. Standard preclinical safety studies would be required to evaluate its safety for potential therapeutic applications.
|
| References | |
| Additional Infomation |
AZ12672857 (CAS#: 945396-55-4) is a potent inhibitor of EphB4 with an IC50 of 1.3 nM. It also inhibits Src-transfected cell proliferation with an IC50 of 2 nM and EphB4 autophosphorylation with an IC50 of 9 nM. It has a molecular formula of C26H30N8O2 and a molecular weight of 486.57. It is a research tool for studying EphB4 and Src kinase signaling.
|
| Molecular Formula |
C26H30N8O2
|
|---|---|
| Molecular Weight |
486.568804264069
|
| Exact Mass |
486.249
|
| CAS # |
945396-55-4
|
| PubChem CID |
49831162
|
| Appearance |
Light brown to brown solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
36
|
| Complexity |
665
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1CCN(CC1)C1C=C(C=C(C=1)N1CCOCC1)NC1N=CC=C(N=1)N(C)C1=CC=CC2=C1C=NN2
|
| InChi Key |
QLFGDTPACJHLRY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H30N8O2/c1-32(24-4-2-3-23-22(24)18-28-31-23)25-5-6-27-26(30-25)29-19-15-20(33-7-11-35-12-8-33)17-21(16-19)34-9-13-36-14-10-34/h2-6,15-18H,7-14H2,1H3,(H,28,31)(H,27,29,30)
|
| Chemical Name |
2-N-(3,5-dimorpholin-4-ylphenyl)-4-N-(1H-indazol-4-yl)-4-N-methylpyrimidine-2,4-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (51.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0552 mL | 10.2760 mL | 20.5520 mL | |
| 5 mM | 0.4110 mL | 2.0552 mL | 4.1104 mL | |
| 10 mM | 0.2055 mL | 1.0276 mL | 2.0552 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
